why choose us

First received: September 20, 2022

Clinical Trial: A Study of Bomedemstat (MK-3543) in Participants With Polycythemia Vera (MK-3543-004)

Study Status: Completed

Recruit Status: RECRUITING

Condition: Polycythemia Vera

Study Type: INTERVENTIONAL


Official Title: A Phase 2 Multi-Center, Open Label Study to Assess the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Bomedemstat in Patients With Polycythemia Vera (PV)

Brief Summary: This is a Phase 2 open label study of an orally administered lysine-specific demethylase 1 (LSD1) inhibitor, bomedemstat, in participants with polycythemia vera.The primary hypothesis is that bomedemstat is a safe and tolerable orally available agent when administered to participants with PV; and inhibition of LSD1 by bomedemstat will induce hematologic response in this population by 36 weeks, improve symptom burden and reduce spleen size in participants with enlarged spleen at baseline.

Read more